NCRI Director Karen Kennedy talks about the new NCRI strategy
Cancer presents vast challenges that will not be overcome by a single organisation working in isolation. In the UK alone, 360,000 people are diagnosed with cancer each year. Research is driving progress in early diagnosis and treatments, and now more than half of those diagnosed with cancer live for more than ten years. But we need to do more, and collaboration and partnership working within the cancer research community are now more important than ever.
We are delighted to be launching the new NCRI strategy for 2017-2022. This is truly a partnership strategy that has been developed following wide-ranging consultation, and ratified by all our Partners.
The NCRI was established in 2001 to drive collaboration between organisations that fund cancer research, and we remain dedicated to our purpose which is to improve health and quality of life by accelerating progress in cancer-related research, through collaboration.
Together, NCRI Partners have since 2002, spent over six billion pounds on cancer-related research. The NCRI exists to ensure that these funds are invested effectively, by avoiding duplication of effort, building research capacity where required, and ensuring cancer research is high quality and relevant.
The NCRI prides itself on being agile and responsive to change and works effectively across charity, government and public sectors to identify areas where it can add value. To address the challenges that cancer presents, we facilitate over 250 meetings a year, and host the UK’s largest cancer conference with over 1,500 delegates. These forums bring together expert groups of researchers, clinicians, health care professionals, patients and funders to share ideas and information, to identify new research opportunities, and to forge the vital partnerships that will accelerate research progress.
Our new strategy states four clear goals that are underpinned by four enabling factors. We will use our intelligence gathering to identify gaps in the research portfolio and develop solutions, do more to bring about improvements in treatments and care for cancer patients and the wider public, and promote innovations in the technologies that support them, and we will ensure that research relating to cancer is translated into benefits as soon as possible.
We are confident that by working together we can realise this bold strategy and we look forward to collaborating with you.